The chokepoints

Each layer of the supply chain has its own physics, its own moat, and its own catalyst calendar. Pick a strait.

Sterile fill-finish capacity

GLP-1 demand turned aseptic fill-finish lines into the scarcest asset in pharma; capacity books out years ahead.

TMO · LLY · NVO · LZAGY · FUJIY · SIMTRA

Stoppers, syringes & drug-contact components

Every injectable passes through elastomer stoppers and glass barrels from two or three qualified suppliers — West's near-monopoly is the textbook choke.

WST · STVN · ATR · DTG.SW · GRRMY · YPHDF · SHLMEDICAL

III

Pharmaceutical glass & vials

Borosilicate vial and cartridge capacity concentrates in three companies; every injectable ramp strains it.

STVN · SHTPY · GLW · GRRMF · NPEGF

Bioprocessing consumables & resins

Biologics manufacturing runs on single-use bags, filters and protein-A resin from an oligopoly with razor-blade economics.

RGEN · DHR · SDMHF · MKKGY · TMO · SOAGY

API & small-molecule reshoring

Most US generic APIs route through China and India; BIOSECURE-era reshoring is funded, dated, and capacity-constrained.

LZAGY · TMO · HKMPY · RDY · AMRX · SGFEF · WUXAY · USANTIBIOTICS

CDMO capacity & the China exodus

WuXi handles a huge share of Western pipelines; every BIOSECURE headline reprices the non-Chinese CDMO bench.

LZAGY · TMO · WUXAY · WXIBF · FUJIY · CRL · SAMSUNGBIOLOGICS

VII

Peptide & oligonucleotide manufacturing

GLP-1s are peptides and the new genetic medicines are oligos — both need specialized synthesis capacity that is genuinely scarce.

BCHMY · LZAGY · A · MRVI · CORDENPHARMA

VIII